The Protein Aggregation & Stability conference at PEGS Europe seeks to highlight the importance in prediction of aggregation propensity affecting stability of solutions and formulations, while exploring new and advanced technologies, strategies and device design to characterize, control and mitigate aggregation.

Preliminary Agenda

ADVANCED STRATEGIES & TECHNOLOGIES IN PARTICLE ANALYTICS

KEYNOTE PRESENTATION: Closing the Analytical 0.1-2 Micron-Size Gap: Why, When and How?

Wim Jiskoot, PhD, Professor, BioTherapeutics, Leiden University

Chemometrics and Advanced Data Analytics for Particle Analytics

Jonas Hoeg Thygesen, PhD, Area Specialist, R&D Microanalysis, Novo Nordisk Pharmatech A/S

Monitoring and Characterizing Aggregation Variants in Co-Formulated Biologic Products: Utilizing 2D Chromatography to Assess Aggregation

Mark Anthony Haverick, PhD, Associate Principal Scientist, MSD

Solution NMR Assessments of Therapeutic Protein Behavior

Mark McCoy, PhD, Principal Scientist, Discovery Chemistry, MSD

ADVANCES IN DEVICE DESIGN TO MINIMISE AGGREGATION

New Design of a Blast Freezer Thawer to Minimize Freeze-Thaw Associated Protein Aggregation

Karoline Bechtold-Peters, PhD, Senior Strategy and Technology Leader, Biologics Technical Development & Manufacturing, Novartis Pharma AG

PREDICTION OF AGGREGATION PROPENSITY

Progress in High Throughput Biophysical Characterization Approaches to Predict Long-Term Physical Stability of Protein Drugs in Pharmaceutical Formulations

Gerhard Winter, PhD, Professor, Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universitat

Thermodynamic Prediction of the Concentration-Dependence of Protein Solutions

Thomas Laue, PhD, Professor Emeritus, Biochemistry, and Molecular Biology; Director, Biomolecular Interaction Technologies Center (BITC), University of New Hampshire

A Mechanistic Approach for the Assessment of Protein Aggregation Propensity in Therapeutic Proteins: Practical Applications in Biopharmaceutical Drug Candidate Selection and Pre-Formulation Development

Danny K. Chou, PharmD, PhD, President, Compassion BioSolution, LLC.



* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean